Results and prognostic factors of hypofractionated stereotactic radiation therapy for primary or metastatic lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 4, 2010, Pages 526-532

  Kim, Haeyoung ^a,b   Ahn, Yong Chan ^b   Park, Hee Chul ^b   Lim, Do Hoon ^b   Nam, Heerim ^b  

^a Seoul National University Hospital   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; HYPOFRACTIONATED STEREOTACTIC RADIATION THERAPY; LUNG CANCER; LUNG METASTASIS; MALE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION DOSE; STEREOTACTIC TREATMENT; TUMOR VOLUME;

EID: 77950973112     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181cbf622     Document Type: Article

References (33)

1. Alexander E III, Moriarty TM, Davis RB, et al. Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 1995;87:34-40.
2. Shirato H, Takamura A, Tomita M, et al. Stereotactic irradiation without whole-brain irradiation for single brain metastasis. Int J Radiat Oncol Biol Phys 1997;37:385-391. (Pubitemid 27138723)
3. Carey Sampson M, Katz A, Constine LS. Stereotactic body radiation therapy for extracranial oligometastases: does the sword have a double edge? Semin Radiat Oncol 2006;16:67-76.
4. Nakagawa K, Aoki Y, Tago M, et al. Megavoltage CT-assisted stereotactic radiosurgery for thoracic tumors: original research in the treatment of thoracic neoplasms. Int J Radiat Oncol Biol Phys 2000;48:449-457.
5. Lee SW, Choi EK, Park HJ, et al. Stereotactic body frame based fractionated radiosurgery on consecutive days for primary or metastatic tumors in the lung. Lung Cancer 2003;40:309-315.
6. Wulf J, Haedinger U, Oppitz U, et al. Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys 2004;60:186-196. (Pubitemid 39165484)
7. Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003;124:1946-1955. (Pubitemid 37433596)
8. Fukumoto S, Shirato H, Shimzu S, et al. Small-volume image-guided radiotherapy using hypofractionated, coplanar, and noncoplanar multiple fields for patients with inoperable Stage I nonsmall cell lung carcinomas. Cancer 2002;95:1546-1553.
9. Wada H, Takai Y, Nemoto K, et al. Univariate analysis of factors correlated with tumor control probability of three-dimensional conformal hypofractionated high-dose radiotherapy for small pulmonary or hepatic tumors. Int J Radiat Oncol Biol Phys 2004;58:1114-1120 (Pubitemid 38314793)
10. Onimaru R, Fujino M, Yamazaki K, et al. Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:374-381.
11. Inoue T, Shimizu S, Onimaru R, et al. Clinical outcomes of stereotactic body radiotherapy for small lung lesions clinically diagnosed as primary lung cancer on radiologic examination. Int J Radiat Oncol Biol Phys 2009;75:683-687.
12. Baumann P, Nyman J, Lax I, et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol 2006;45:787-795. (Pubitemid 44423123)
13. Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007;2:S94-S100. (Pubitemid 47183602)
14. Guckenberger M, Wulf J, Mueller G, et al. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys 2009; 74:47-54.
15. McCammon R, Schefter TE, Gaspar LE, et al. Observation of a dosecontrol relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2009;73:112-118.
16. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-214. (Pubitemid 11167383)
17. Common Terminology Criteria for Adverse Events version 3.0 (CTCAEv3.0) [Cancer Therapy Evaluation Program Web site]. August 9, 2006. Available at: http://ctep.cancer.gov/reporting/ctc.html. Accessed November 11, 2008.
18. Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009; 27:3290-3296.
19. Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 2009;15:4-9.
20. Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005;63:1427-1431. (Pubitemid 41628038)
21. Uematsu M, Shioda A, Suda A, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 2001;51:666-670. (Pubitemid 32951783)
22. Zimmermann FB, Geinitz H, Schill S, et al. Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC). Acta Oncol 2006;45:796-801. (Pubitemid 44423124)
23. Xia T, Li H, Sun Q, et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable stage I/II non-smallcell lung cancer. Int J Radiat Oncol Biol Phys 2006;66:117-125. (Pubitemid 44175645)
24. Nyman J, Johansson KA, Hulten U. Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer-mature results for medically inoperable patients. Lung Cancer 2006;51:97-103. (Pubitemid 43088629)
25. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006;24:4833-4839. (Pubitemid 46630909)
26. Onimaru R, Shirato H, Shimizu S, et al. Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol Phys 2003;56:126-135. (Pubitemid 36403684)
27. Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009;27:1572-1578.
28. http://www.clinicaltrials.gov/ct/show/NCT00238875.
29. http://www.rtog.org/members/protocols/0236/0236.pdf.
30. Nagata Y, Matsuo Y, Takayama K, et al. Current status of stereotactic body radiotherapy for lung cancer. Int J Clin Oncol 2007;12:3-7. (Pubitemid 46472560)
31. Nagata Y, Matsuo Y, Takayama K. Survay of SBRT in Japan. Int J Radiat Oncol Biol Phys 2006;66 (suppl 1):s150-s151.
32. Yamashita H, Nakagawa K, Nakamura N, et al. Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol 2007;2:21.
33. Milano MT, Constine LS, Okunieff P. Normal tissue toxicity after small field hypofractionated stereotactic body radiation. Radiat Oncol 2008; 3:36.